Articles From: Fastenal Company Announces Conference Call to Review 2014 First Quarter Earnings to Fate Therapeutics, Inc. Announces Pricing of Initial Public Offering


2014/3/31
WINONA, Minn., March 31, 2014 (GLOBE NEWSWIRE) -- Fastenal Company (Nasdaq:FAST) announced the date and time for their conference call to review 2014 first quarter results, as well as current operations.
Sign-up for Fastenal Company Announces Conference Call to Review 2014 First Quarter Earnings investment picks
2013/12/20
WINONA, Minn., Dec.
Sign-up for Fastenal Company Provides 2013 Fourth Quarter Update investment picks
2014/1/15
WINONA, Minn., Jan.
Sign-up for Fastenal Company Reports 2013 Fourth Quarter and Annual Earnings investment picks
WINONA, Minn., Oct.
Sign-up for Fastenal Company Reports 2013 Third Quarter Earnings investment picks
2014/4/11
WINONA, Minn., April 11, 2014 (GLOBE NEWSWIRE) -- Fastenal Company of Winona, MN (Nasdaq:FAST) reported the results of the quarter ended March 31, 2014.
Sign-up for Fastenal Company Reports 2014 First Quarter Earnings investment picks
2014/4/11
By Erin McCarthy Fastenal Co.
Sign-up for Fastenal Profit Rises 2.6%, Revenue Up 8.7% investment picks
2014/3/25
By Benjamin Pimentel, MarketWatch SAN FRANCISCO (MarketWatch) -- Twitter shares took a hit after the social network posted slower-than-expected user growth last month, which isn't a problem that the microblogging site could easily fix, an analyst said Tuesday.
Sign-up for Faster growth on Twitter will take time, analyst says investment picks
2014/4/10
http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=11G014374-001&sourceType=1 http://www.marketwire.com/library/MwGo/2014/4/9/11G014374/FastFunds_Logo-325888333345.gif WEST PALM BEACH, FL--(Marketwired - April 10, 2014) - FastFunds Financial Corporation ("FastFunds" or the "Company") (PINKSHEETS: FFFC) and its wholly-owned subsidiary, Cannabis Angel, Inc., a company involved in providing financing alternatives, corporate finance and general management consulting services to early-stage cannabis companies and projects, provide the following updates regarding it recent business activities.
Sign-up for FastFunds Financial Corporation Updates Recent Activities of Cannabis Angel Subsidiary and Partners investment picks
2014/2/12
Fastweb would like to help empower African American students this Black History month by highlighting the unique scholarships available to today’s students, the history-makers of tomorrow.
Sign-up for Fastweb Aims to Empower Students During Black History Month and Through Their Entire College Journey investment picks
2014/3/12
Fastweb has gathered an impressive list of scholarships that are specifically meant for women who are currently studying at college or are college bound.
Sign-up for Fastweb Spotlights Scholarship Opportunities for Women investment picks
Fastweb ( www.fastweb.com ), the leading website for scholarship and financial aid information and a member of the Monster.com network, introduced for the new school year, Student Soundoff.
Sign-up for Fastweb’s Student Soundoff Program Speaks to Students investment picks
2013/8/30
JOHANNESBURG , Aug.
Sign-up for Fatal Accident at Bokoni Mine investment picks
Fatal Accident at Bokoni Mine Canada NewsWire Immediately after the accident Bokoni mine management stopped operations at the affected section.
Sign-up for Fatal Accident at Bokoni Mine investment picks
Fatal accident at Bokoni Mine Canada NewsWire The board of directors and management of the Company and Bokoni extend their condolences to both the family and colleagues of the deceased employee.
Sign-up for Fatal accident at Bokoni Mine investment picks
JOHANNESBURG , Sept.
Sign-up for Fatal accident at Bokoni Mine investment picks
2014/1/10
Fatal accident at Excellon's Platosa Mine Canada NewsWire TORONTO , Jan.
Sign-up for Fatal accident at Excellon's Platosa Mine investment picks
2014/3/6
SAN DIEGO, March 6, 2014 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (Nasdaq:FATE) , a biopharmaceutical company engaged in the discovery and development of adult stem cell modulators to treat orphan diseases, announced today the publication of an article in the journal Stem Cell Reports by Fate scientists demonstrating high-throughput derivation of human induced pluripotent stem cells (hiPSCs) that exhibit characteristics necessary for therapeutic application.
Sign-up for Fate Therapeutics Announces Publication of Its Proprietary Stem Cell Modulation Platform for Developing iPSC-Based Regenerative Therapeutics investment picks
2014/3/17
SAN DIEGO, March 17, 2014 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (Nasdaq:FATE) , a biopharmaceutical company engaged in the discovery and development of adult stem cell modulators to treat orphan diseases, announced today that Dr.
Sign-up for Fate Therapeutics Appoints Dr. Robert S. Epstein to Its Board of Directors investment picks
2014/3/12
First Patient Enrolled in PUMA Study SAN DIEGO, March 12, 2014 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (Nasdaq:FATE) , a biopharmaceutical company engaged in the discovery and development of adult stem cell modulators to treat orphan diseases, announced today the enrollment of the first patient in its "PUMA" ( P ROHEMA ® in UM bilical cord blood transplant in A dults) study, a Phase 2 clinical trial of PROHEMA ® (16, 16-dimethyl prostaglandin E2, or dmPGE2, modulated cord blood) using the Company's nutrient-rich media formulation.
Sign-up for Fate Therapeutics Commences Phase 2 Clinical Trial of PROHEMA(R) for the Treatment of Hematologic Malignancies investment picks
2014/2/28
SAN DIEGO, Feb.
Sign-up for Fate Therapeutics Observes Rare Disease Day 2014 investment picks
2014/3/17
Phase 2 PUMA Study of PROHEMA® Initiated - Interim Data Expected in 2H14 About Fate Therapeutics, Inc. Fate Therapeutics is a clinical-stage biopharmaceutical company engaged in the discovery and development of pharmacologic modulators of adult stem cells to treat orphan diseases.
Sign-up for Fate Therapeutics Reports Fourth Quarter and Full Year 2013 Financial Results investment picks
Cleared Key Milestones for Resumption of ProHema Phase 2 Clinical Trial Forward-Looking Statements This release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the therapeutic potential of our programs for the modulation of adult stem cells to treat orphan diseases, including ProHema and our Wnt7a protein analogs, and our preclinical and clinical development plans, including our ability to resume enrollment of the ProHema-03 trial using our NRM formulation in the first half of 2014 and to generate full data on the primary and major secondary endpoints related to engraftment in mid-2015, the timing and results of the planned safety reviews for the ProHema-03 trial, our ability to initiate IND-enabling activities for our Wnt7a-analog program, our ability to advance a Wnt7a protein analog into Phase 1 clinical trials in 2015, and our projected cash runway.
Sign-up for Fate Therapeutics Reports Third Quarter 2013 Financial Results investment picks
2014/4/10
SAN DIEGO, April 10, 2014 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (Nasdaq:FATE) , a biopharmaceutical company engaged in the discovery and development of adult stem cell modulators to treat orphan diseases, announced today that the U.S. Patent and Trademark Office (PTO) has issued Patent No.
Sign-up for Fate Therapeutics Secures U.S. Patent for Class of Small Molecule Modulators Key to the Development of iPSC-Based Therapeutics investment picks
2014/2/27
SAN DIEGO, Feb.
Sign-up for Fate Therapeutics to Present at Upcoming March Conferences investment picks
2013/10/2
SAN DIEGO, Oct.
Sign-up for Fate Therapeutics to Present at World Muscle Society Congress investment picks
2014/3/11
SAN DIEGO, March 11, 2014 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (Nasdaq:FATE) , a biopharmaceutical company engaged in the discovery and development of adult stem cell modulators to treat orphan diseases, today announced that the Company will host a conference call and live audio webcast on Monday, March 17, 2014, at 5:00 p.m. EDT to report its fourth quarter and full year 2013 financial results and provide a corporate update.
Sign-up for Fate Therapeutics to Webcast Conference Call Reporting Fourth Quarter and Full Year 2013 Financial Results on March 17, 2014 investment picks
2013/10/1
SAN DIEGO, Oct.
Sign-up for Fate Therapeutics, Inc. Announces Pricing of Initial Public Offering investment picks
Start Premium Trial Register For Free

P F Fund Financial Data (13,000+ funds)
P F Stock Financial Data (7,000+ stocks)
P F Stock and Fund Screeners (basic)
P F Investing Articles and Market Commentary
P F Articles Archive (>30 days)
P F Discuss (dozens of stock, fund, bond, and general bulletin boards)
P F Portfolio Manager (basic)
P F Morningstar Investment Classroom
P F Access Your Portfolio Anytime, Anywhere via Your Mobile Device
P   Morningstar Fund Analyst Reports (full research on 1,700 funds, ETFs, and CEFs)
P   Morningstar Stock Analyst Reports (full research on more than 1,100 stocks)
P   Portfolio Manager (advanced with 10 X-Ray analyses, including recommendations)
P   Portfolio Monitor (monthly and on-demand personalized portfolio statements)
P   Morningstar Proprietary Stock Information (stock star ratings, buy/sell prices, economic moat ratings, and more)
P   Morningstar 5-Star Stock and Fund Favorites & Red Flags eNewsletters
P   Premium Stock and Fund Screeners (advanced with nearly infinite ways to find the best securities for you)
P   Discounts on Morningstar newsletters, books, seminars, and more

Sign-up to Morningstar


Basic Access

Articles and Videos
Morningstar video reports, articles, data, and tools. Dig into our lineup of e-newsletters and investing classroom courses outlining sensible strategies for maximizing your investments.
Morningstar Discuss
Follow the buzz on individual stocks or fund families. Plus, read the latest posts from Morningstar members and analysts.
Portfolio Manager
Track your investments and watch lists with our Portfolio Manager. Customize your view with our comprehensive stock, fund, and ETF data.

Access these features and more when you sign up for Free Membership.
Join Morningstar today. It's Free.

Unlimited Access

Analyst Research
Gather in-depth, actionable insight on over 3,700 stock and mutual funds covered by Morningstar analysts. View our mutual fund Analyst Reports favored by professionals, savvy experienced investors, and new investors researching options for retirement savings, college plans, or other investment needs.
Portfolio X-Ray®
Ensure your portfolio is positioned exactly how you want with Morningstar's X-Ray Interpreter and Stock Intersection tools. A Barron's "Best of the Web" award winner for five years running, X-Ray Interpreter goes under the hood of your portfolio to provide a useful allocation, sector, and geographic analysis. And you can discover how much of a stock you really own, individually and through mutual funds, with Stock Intersection.
Investment Picks
Find new 5-star stocks (greatly undervalued companies) to consider daily. Our 5-star stock rating is a proven winner, consistently beating benchmarks like the S&P 500. Plus, browse our Fund Analyst Picks and Stewardship Grades to find shareholder-friendly mutual funds that are poised for outperformance.
Portfolio Monitor
Get a clear view of your investments with personalized reports about your portfolio. Receive monthly statements and generate reports on-demand to help you stay on track to meet your investment goals.

Access these features and more when you sign up for Premium Membership.
Start your free 14-day trial today online
Your subscription may be tax deductible. Please contact your tax advisor.

Articles From: Fastenal Company Announces Conference Call to Review 2014 First Quarter Earnings to Fate Therapeutics, Inc. Announces Pricing of Initial Public Offering
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity